Pharmaceutical market access vice presidents, executive directors, market access marketing, and brand leads:
In collaboration with the private sector, the Centers for Medicare & Medicaid Services (CMS) is transforming payment, delivery, and care in Medicare Advantage (MA). Policies and significant MA investment are fueling enrollment growth promoting innovation and empowerment of MA plan sponsors to cover more benefits and supplemental coverage to improve enrollee choice and quality of care.
Enrollment in 2022 is projected to reach 29.5 million members, nearly half of all Medicare-eligible individuals. The MA plan enrollee population is increasingly diverse, as demonstrated by demographics: 53% of Latino and 49% of black beneficiaries now choose MA, higher than the overall share of the Medicare population.
The impact of the pandemic has brought health and care disparities into a sharper focus and highlighted the urgency for Medicare plan sponsors to address health and care equity gaps. To elevate and accelerate the drive to health equity, CMS is proposing a pay boost of 8% for 2023 preliminary rates.
MA plan sponsors in collaboration with their network providers are driving innovation in the delivery of care through member engagement and services to improve quality and outcomes. Are you positioned to capitalize on opportunities for deeper collaboration with plan sponsors and their providers to address disparities, improve outcomes, and drive results on behalf of your brand and related disease state(s)?
Are you looking for deeper customer collaboration opportunities to address disparities with MA plan sponsors and their providers?
Disease and brand resources that may be leveraged to address disparities in their relevant patient populations include:
Guideline-based treatment regimens
Patient support educational resources aligned to CMS health literacy guidance
Reimbursement/HUB support services
The challenge is to secure plan sponsor and provider uptake and use of these resources by building a presence in the clinical workflow at the electronic health record/telehealth point of patient care.
Aventria can help you build a presence in the clinical workflow and launch a differentiated disparities of health and care offering.
Presenting Aventria Health Group’s Proprietary and Proven Outcome Guided Engagement® (OGE®) Digital Platform
Our proven and proprietary OGE digital platform can help you drive credible patient and caregiver engagement by delivering disease and drug educational resources as well as tech-enabled HUB links at the electronic health record and telehealth point(s) of care.
To learn more about the Aventria OGE digital platform and how we can help you launch a differentiated disparities offering at the point of care, please reach out to:
Dave Dierk, Co-President, 30-year sales and marketing thought leader in pharmaceutical diagnostics, biomedical, long-term care, managed care, employer, and pharmacy communications, at dave.dierk@aventriahealth.com.
Paul G. Pochtar, RPh, SVP of Pharmaceutical
Commercialization and Access Strategies, extensive experience in leading successful market access commercialization of both primary care and specialty pharmaceuticals throughout their life cycle, including several landmark oncology products,
Making a difference in patient care by helping patients, providers, and payers collaborate on shared priorities